Whitney Hunter, APRN
Women's Health · Oklahoma City, OKNPI 1164842514
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Among women's health clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$552
- Merck$430
- Daiichi Sankyo Inc.$347
- Genmab U.S., Inc.$296
- AbbVie$233
- Stemline Therapeutics Inc.$177
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,087100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $552 |
| Merck | 23 | $430 |
| Daiichi Sankyo Inc. | 15 | $347 |
| Genmab U.S., Inc. | 7 | $296 |
| AbbVie | 9 | $233 |
| Stemline Therapeutics Inc. | 10 | $177 |
| Genentech USA, Inc. | 7 | $149 |
| Astellas Pharma US Inc | 8 | $148 |
| Immunogen, Inc. | 2 | $147 |
| Lilly USA, LLC | 9 | $135 |
| GSK | 1 | $117 |
| Seagen Inc. | 5 | $89 |
| Tersera Therapeutics LLC | 3 | $71 |
| Myriad Genetic Laboratories, Inc. | 4 | $61 |
| Eisai Inc. | 1 | $31 |
| Clovis Oncology, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $21 |
| Caris MPI, Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,087 in reported general payments places this provider in the 90th percentile of 62 women's health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $9,343 |
| Gabapentin | 34 | $364 |
| Potassium Chloride | 18 | $245 |
| Prochlorperazine Maleate | 15 | $243 |
| Ondansetron OdtOndansetron | 13 | $187 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $169 |
| Fluconazole | 16 | $65 |
Paid to pharmacies, not to this prescriber.
Other women's health in Oklahoma City
- Hilary MillerOklahoma City$38K
- Beverly CotnerOklahoma City$4K
- Bethany CookOklahoma City$3K
- Erika RumbleOklahoma City$2K
- Jaclyn ShaverOklahoma City$2K
- Meredith DewitteOklahoma City$2K
- Charnelle DeanOklahoma City$711
- Joyce TowOklahoma City$507
- Maria MeyerOklahoma City$378
- Amanda KenneyOklahoma City$343
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.